Positive phase 3 results for Molecular Partner’s most advanced molecule

19.07.2018 15:04

Related tags

Eye

Allergan and Molecular Partners announced the release of two positive phase 3 clinical trials of abicipar for the Treatment in Patients with Neovascular Age-Related Macular Degeneration. The filing for abicipar is planned for the first half of 2019.  

The two clinical trials, SEQUOIA and CEDAR, are identical global phase 3 studies designed to assess the efficacy and safety of abicipar compared with ranibizumab in treatment-naïve patients with neovascular age-related macular degeneration (AMD).  The primary endpoint measured the proportion of treated patients with stable vision at week 52. In both studies abicipar demonstrated similar efficacy after 6 or 8 injections, compared to 13 ranibizumab injections in the first year of this study.

“Abicipar could transform the way physicians manage AMD with anti-VEGF therapy.  Today’s anti-VEGFs were designed for monthly or bimonthly dosing.  In the real world, patients have difficulty adhering to the schedule, which places their vision at risk.   The adopted treat-and extend approach, while practical, is supported by limited data and in certain cases shows sub-optimal visual outcomes.  Treat-and-extend amounts to a compromise for most patients who are unable or unwilling to comply with frequent injections.  Abicipar could be the first and only 12- week anti-VEGF treatment that improves visual outcomes in a real world setting for a large number of AMD patients,” said Raj Maturi, MD, Midwest Eye Institute & Associate Professor Ophthalmology, Indiana University School of Medicine.

Very important milestone for Molecular Partners
 “We are very excited to see that the most advanced DARPin molecule, abicipar, reaches its primary endpoint in phase 3. This is a very important milestone for Molecular Partners and the DARPin technology in general,” said Patrick Amstutz, PhD, CEO of Molecular Partners. “We are very pleased to see that abicipar can indeed help patients in need with less frequent dosing which was the key point when we generated abicipar in the first place,” added Michael T. Stumpp, PhD, COO of Molecular Partners.

Abicipar pegol is a long-acting potent antagonist of vascular endothelial growth factor (VEGF), which is based on the DARPin technology. Abicipar pegol was licensed to Allergan from Molecular Partners in May 2011.

(Press release)

Please login or
register to comment

Please login or sign up to comment. Commenting guidelines

Principal

Partners

Contributors

By continuing to use this website you agree with our TERMS AND CONDITIONS

In order to provide the best quality for you, our system uses "cookies", which are stored on your device. Cookies are necessary to identify what information (job advertisement, questionnaire, etc) you have already seen. IP address is used for the same purposes as described above.

When creating a profile, applying to the newsletter, job subscriptions and etc, you agree that the data, which you have entered, will be stored and processed in the system in order to provide services, which you have applied for.

We do NOT sell your personal data to any 3rd party services.

You must be 18 or older years old to use our services. If you are underage, you must have a permission to use our services from your parent or guardian. It is necessary in order to store and process your data.

By continuing to use our services, you agree with the these terms. You can withdraw your agreement at any time, by deleting cookies from your device and by sending request for deleting your data to the administrator.